Title
Igg seroconversion and pathophysiology in severe acute respiratory syndrome coronavirus 2 infection
Date Issued
01 January 2021
Access level
open access
Resource Type
journal article
Author(s)
Staines H.M.
Clark D.J.
Adams E.R.
Augustin Y.
Byrne R.L.
Cocozza M.
Cubas-Atienzar A.I.
Cuevas L.E.
Cusinato M.
Davies B.M.O.
Davis M.
Davis P.
Duvoix A.
Eckersley N.M.
Forton D.
Fraser A.J.
Garrod G.
Hadcocks L.
Hu Q.
Johnson M.
Kay G.A.
Klekotko K.
Lewis Z.
Macallan D.C.
Mensah-Kane J.
Menzies S.
Monahan I.
Moore C.M.
Nebe-Von-Caron G.
Owen S.I.
Sainter C.
Sall A.A.
Schouten J.
Williams C.T.
Wilkins J.
Woolston K.
Fitchett J.R.A.
Krishna S.
Planche T.
St. George's University of London
Publisher(s)
Centers for Disease Control and Prevention (CDC)
Abstract
We investigated the dynamics of seroconversion in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. During March 29-May 22, 2020, we collected serum samples and associated clinical data from 177 persons in London, UK, who had SARS-CoV-2 infection. We measured IgG against SARS-CoV-2 and compared antibody levels with patient outcomes, demographic information, and laboratory characteristics. We found that 2.0%-8.5% of persons did not seroconvert 3-6 weeks after infection. Persons who seroconverted were older, were more likely to have concurrent conditions, and had higher levels of inflammatory markers. Non-White persons had higher antibody concentrations than those who identified as White; these concentrations did not decline during follow-up. Serologic assay results correlated with disease outcome, race, and other risk factors for severe SARS-CoV-2 infection. Serologic assays can be used in surveillance to clarify the duration and protective nature of humoral responses to SARS-CoV-2 infection.
Start page
85
End page
91
Volume
27
Issue
1
Language
English
OCDE Knowledge area
Epidemiología
Enfermedades infecciosas
Scopus EID
2-s2.0-85098581626
PubMed ID
Source
Emerging Infectious Diseases
ISSN of the container
10806040
Sponsor(s)
This study was supported by a UK Department for International Development/Wellcome Trust Epidemic Preparedness coronavirus grant (grant no. 220764/Z/20/Z) to J.R.A.F., S.K., H.M.S., E.R.A., L.E.C., A.A.S. and by the Rosetrees Trust and the John Black Charitable Foundation (grant no. M959) to H.M.S., D.J.C., T.P., S.K., and J.R.A.F. In addition, D.E.K. is supported by Medical Research Council, UK, under fellowship no. MR/P019978/2. H.M.S. is supported by the Wellcome Trust Institutional Strategic Support Fund (204809/Z/16/Z) awarded to St George’s, University of London, London.
Sources of information:
Directorio de Producción Científica
Scopus